Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...

Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among 69 executives at ...

Sanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments. Why ...

Roche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate ...

Dutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, ...

Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that ...

France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of ...

Genmab and AbbVie's bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma ...

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to ...

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion ...

Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an ...

Boehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with ...